Xinda biology completed the financing of round D of 260 million US dollars

Source: Xinda biology 2016-11-29 on November 29, 2016, Xinda biopharmaceutical (Suzhou) Co., Ltd., a biopharmaceutical company focusing on the research and development and production of new monoclonal antibody drugs, announced the successful completion of the D round financing of 260 million US dollars (1.7 billion RMB) The financing is led by the advanced manufacturing industry investment fund managed by SDIC Innovation Investment Management Co., Ltd ("SDIC innovation"), and jointly funded by new investors such as Guoshou health fund, Licheng asset, China Ping An, Taikang Insurance Group and original investors such as Junlian capital, Temasek and Hillhead capital Founded in August 2011, Cinda biology has established a product chain including 12 new antibody drugs, and the treatment field covers four major disease fields, including tumor, autoimmune disease, fundus disease and cardiovascular disease Four products have been approved for clinical research, three of which have officially entered clinical phase III research In March and October 2015, Cinda biology reached comprehensive strategic cooperation with Lilly Pharmaceutical Co., Ltd of the United States twice, and obtained 3.3 billion US dollars in down payment and potential milestone payments, creating several "China first" This is not only the first time that the overseas market of biological drugs invented by the Chinese has been transferred to the world's top 500 pharmaceutical companies, but also the first time that innovative drugs made in China have sold at international prices Based on the innovation achievements of Cinda bio, in June 2015, as a representative of China's outstanding innovative enterprises, Cinda bio participated in the "Sixth China US innovation dialogue" held at the invitation of the State Council Dr Yu Dechao, chairman of the company, delivered a speech on China's innovation at the conference The people's daily and the Wall Street Journal made in-depth reports on the achievements of independent innovation and successful cases of international cooperation of Cinda bio on their front page headlines twice Xinda bio's innovation achievements were successfully selected into the 2015 "top ten progress of Chinese medicine and Biotechnology", and in June 2016, Xinda bio was invited to participate in the national "12th Five Year" science and technology innovation achievements exhibition organized by 15 ministries and commissions including the central organization department and the Ministry of science and technology, which was affirmed by the national leaders Liu Yandong, member of the Political Bureau of the Central Committee and vice premier of the State Council, visited Xinda in June 2016 for investigation and spoke highly of the innovation achievements of Xinda biology "We are a young company, which has grown rapidly in the past five years With the strong support of investors and the government, and through the joint efforts and sincere cooperation of the team, the company has made significant progress in new drug research and development, industrialization base construction, international cooperation and other aspects, and successfully completed various goals." Said Dr Yu Dechao, founder and chairman of Xinda biology“ I'm glad that Xinda's achievements and development potential have been recognized by new investors such as China investment innovation, China Life Insurance, Licheng asset management, China Ping An, Taikang Insurance Group, etc This financing will help Xinda better grasp the development opportunities in the rapidly developing domestic bio pharmaceutical market, and develop high-quality high-end bio pharmaceuticals that can be used by Chinese people as soon as possible " Mr LV Dazhong, general manager of SDIC innovation, said, "Xinda biology is a rising star enterprise in China's biopharmaceutical industry China's biopharmaceutical industry is in a golden period of rapid development We are very happy to cooperate with the top elite team in the biopharmaceutical industry Prior to the investment decision, we made a comprehensive and in-depth due diligence on Xinda's new drug varieties, development capabilities, product quality and production base According to the survey results, we believe that Sinda biology has great potential for development and is expected to become the top biopharmaceutical company in the world " According to statistics, the financing amount of Cinda bio ranked first in the whole biomedical industry of China and even in the global non IPO Financing in 2016 This financing is mainly used to support the high standard operation of Xinda new drug R & D, expansion of production capacity and industrialization base At the same time, this financing event will once again attract the attention of domestic and foreign investment institutions to China's biomedical market, which is expected to accelerate the development of domestic biomedical industry About Xinda biology, founded in 2011, is committed to the development and production of new antibody drugs for the treatment of various difficult diseases endangering human health and life, to meet the huge demand of the domestic and foreign pharmaceutical market Since its establishment, the company has stood out among many domestic biopharmaceutical companies with its innovative R & D ideas and international operation mode, and won the favor of famous investment institutions such as SDIC innovation, China Life Insurance, Licheng asset, China Ping An, Taikang Insurance Group, Junlian capital, Temasek, fidelity group, Lilly Asia fund, etc., as well as the United States Lilly Pharmaceutical Group has established in-depth product cooperation It is the ideal and goal of Xinda biology to develop high-quality biopharmaceuticals that are available to all Chinese people About SDIC innovation, SDIC innovation was established in July 2009 It is a professional private equity management organization that operates independently according to the market-oriented requirements SDIC innovation directly or indirectly manages more than 50 billion yuan of funds, which covers state-owned capital, private capital, social security fund and insurance fund It is one of the largest professional private equity management institutions in China SDIC is a state-owned investment holding company approved by the State Council, an important state-owned backbone enterprise directly managed by the central government, the first batch of pilot units of state-owned capital investment companies by the state owned assets supervision and Administration Commission of the State Council, and an important platform for the national development and Reform Commission to promote the implementation of major decisions and plans of the central government and major national strategies In the annual performance appraisal of the SASAC of the State Council, it was awarded A-level, and was rated as "outstanding performance enterprise" for four consecutive terms, forming four strategic business units: basic industry, forward-looking strategic industry, financial and service industry and international business.